<code id='6DD24B668A'></code><style id='6DD24B668A'></style>
    • <acronym id='6DD24B668A'></acronym>
      <center id='6DD24B668A'><center id='6DD24B668A'><tfoot id='6DD24B668A'></tfoot></center><abbr id='6DD24B668A'><dir id='6DD24B668A'><tfoot id='6DD24B668A'></tfoot><noframes id='6DD24B668A'>

    • <optgroup id='6DD24B668A'><strike id='6DD24B668A'><sup id='6DD24B668A'></sup></strike><code id='6DD24B668A'></code></optgroup>
        1. <b id='6DD24B668A'><label id='6DD24B668A'><select id='6DD24B668A'><dt id='6DD24B668A'><span id='6DD24B668A'></span></dt></select></label></b><u id='6DD24B668A'></u>
          <i id='6DD24B668A'><strike id='6DD24B668A'><tt id='6DD24B668A'><pre id='6DD24B668A'></pre></tt></strike></i>

          hotspot

          hotspot

          author:comprehensive    Page View:328
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Biogen’s boardroom scandal saddles CEO with first crisis
          Biogen’s boardroom scandal saddles CEO with first crisis

          ChrisViehbachertookoverasBiogenCEOinNovember.SuzanneKreiter/Globestaff;PhotoillustrationAlexHogan/ST

          read more
          Medical leaders decry Supreme Court decision on affirmative action
          Medical leaders decry Supreme Court decision on affirmative action

          STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

          read more

          Biden administration begins canceling student loan debt for 804,000 borrowers

          9:50EducationSecretaryMiguelCardonaspeaksduringaback-to-schoolK-12CybersecuritySummitintheEastRoomof